Pharma Equity Group ASOCSE:PEG -4.44% Interest Coverage is 0 (At Loss) as of Dec. 2025. The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, Pharma Equity Group AS ranks worse than 265251.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Pharma Equity Group AS's
Operating Income
for the
six
months ended in Dec. 2025 was kr-16.72 Mil. Pharma Equity Group AS's Interest Expense for the
six
months ended in Dec. 2025 was kr-1.11 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Pharma Equity Group AS's Interest Coverage or its related term are showing as below:
OCSE:PEG's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07 * Ranked among companies with meaningful Interest Coverage only.
Pharma Equity Group AS (OCSE:PEG) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Pharma Equity Group AS Interest Coverage Related Terms
Pharma Equity Group AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Pharma Equity Group AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OCSE:PEG vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's Interest Coverage falls into.
Pharma Equity Group AS Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Pharma Equity Group AS did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Pharma Equity Group AS (OCSE:PEG) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #999999 out of 377 companies in the Biotechnology industry.
Is Pharma Equity Group AS's Interest Coverage too high?
Pharma Equity Group AS's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Pharma Equity Group AS ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #999999 out of 377 companies for Interest Coverage. This places Pharma Equity Group AS in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 